Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

V116 (PCV21) was more cost-effective than PCV20 alone and PCV15 plus PPSV23 for the prevention of adult pneumococcal disease.

Pneumococcal Vaccine market Forecast to Surge to US$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR ...

Also in Health Watch, a new study says drinking a small glass of wine a day may actually protect your heart, and the CDC says anyone over 50 should get the pneumococcal vaccine.

Medicare Advantage plans, sometimes called Part C, also cover the pneumonia vaccine. Pneumococcal vaccines can prevent common bacterial infections from Streptococcus pneumoniae. There are two ...